PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

A2A Adenosine Receptor

SBKB [doi:10.3942/psi_sgkb/fm_2011_5]
Featured System - May 2011
Short description: With proteins, small motions often have large effects.

With proteins, small motions often have large effects. A new structure of the A2A adenosine receptor reveals these motions for an important class of proteins: the G protein-coupled receptors. GPCRs transmit messages across cell membranes, capturing signaling molecules like adrenaline and dopamine, shifting shape, and launching a cascade of messages inside the cell. The atomic details of this signaling has been largely a mystery, since previous structures show the receptor in an inactive state. The new structure fills out the story, and captures the receptor in the activated state, after it has bound to its signaling ligand.

Signaling with Nucleosides

Adenosine receptors are found on cells throughout the body, where they play many different roles. There are four different kinds, each with a different spectrum of responses when activated, controlling diverse processes such as pain, blood flow, respiration, and sleep. Often, the different receptors can have opposite effects. For instance, some forms enhance inflammation when they bind to adenosine, but the A2A adenosine receptor reduces inflammation. This makes them quite challenging as targets for drug action, since it is important to block only the desired receptor, and not the others.

Inflammatory Responses

The A2A adenosine receptor plays an important role in controlling inflammatory responses, and thus is a target for development of anti-inflammatory drugs. For instance, a drug that binds to this receptor and activates it could be useful for the treatment of asthma and COPD (chronic obstructive pulmonary disease), two diseases where the lungs become inflamed, limiting the amount of air reaching the body. This type of drug is termed an "agonist", as opposed to "antagonists" that block the action of the target protein. Researchers have been searching for both types of drugs: agonists to activate the A2A receptor, and antagonists to block other receptors that increase inflammation.

Shifting Shapes

The new structure, solved by Ray Stevens and coworkers at PSI, captures the A2A adenosine receptor bound to an effective agonist drug (PDB entry 3qak). The receptor adopts a slightly different shape than that seen in a previous structure with an antagonist drug (PDB entry 3eml). The receptor is composed of seven helices stacked side-by-side, and these helices slide relative to one another when the drug binds. The ribose portion of the drug seems to be the key player in this motion. Both the agonist and antagonist have a similar adenine ring, but only the agonist has a typical nucleoside sugar. It interacts with the helices surrounding the binding site, shifting them by several Angstroms. This motion is propagated inside, where it is presumably sensed by G-proteins, leading to the signaling cascade. To take a closer look at this motion, the JSmol tab below displays an interactive JSmol.

The JSmol tab below displays an interactive JSmol

RNA Chaperone NMB1681 (PDB entry 3mw6)

The crystal structure was solved using a fragment of the NMB1681 that includes the RNA-binding core and a short segment of the flexible tail. In this Jmol, the cores of the six independent structures are overlapped, so you can see some of the range of motion of the flexible tail. Use the buttons to turn the structures on and off, and to look at a spacefilling representation that shows the positively-charged amino acids.

References

  1. Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science Express doi:10.1126/science.1202793.

  2. Jaakola, V.-P. et al. The 2.6 Angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217 (2008).

  3. Polosa, R. and Blackburn, M. R. Adenosine receptors at targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends Pharm. Sci. 30, 528-535 (2009).

  4. Jacobson, K. A. and Gao, Z.-G. Adenosine receptors as therapeutic targets. Nature Rev. Drug. Discov. 5, 247-264 (2006).

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health